Skip to main content
Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.300
+0.090 (2.14%)
At close: Nov 13, 2026, 4:00 PM EST
4.360
+0.060 (1.40%)
After-hours: Nov 13, 2026, 7:25 PM EST

Atea Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-----351.37
Revenue Growth
-----622.49%
Gross Profit
-143.97-146.53-83.37-70.61-62.39184.16
Operating Income
-171.83-179.4-132.22-120.53-111.1138.38
Net Income
-155.4-158.35-168.39-135.96-115.91121.19
Earnings Per Share
-1.96-1.94-2.00-1.63-1.391.37
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
191.2301.83454.72578.11646.71764.38
Total Debt
0.210.841.642.43.120.2
Net Cash (Debt)
190.99300.99453.08575.7643.59764.18
Net Cash Growth
-41.82%-33.57%-21.30%-10.55%-15.78%-10.11%
Net Cash Per Share
2.413.695.386.907.738.66

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-140.57-132.03-135.5-85.4-120.98-87.01
Capital Expenditures
-----1.94-0
Free Cash Flow
-140.57-132.03-135.5-85.4-122.93-87.01
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----52.41%
Operating Margin
-----39.38%
Pretax Margin
-----39.44%
Profit Margin
-----34.49%
FCF Margin
------24.76%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----6.13
Forward PE
-4.424.424.424.424.42
PS Ratio
-----2.11